Diligence memo · auto-generated · as of July 2, 2026
PhAST Corp.
PhAST Corp. looks fair against its niche peers and is active on financing cadence.
Businessfiled
PhAST Corp. operates in Biotechnology, based in BOSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
PhAST Corp. has raised $19M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2021-10-04.
Most recent recorded round closed around 2025-04-11.
Valuation (modeled)modeled
Provath models PhAST Corp. at approximately $13M (range $3.8M–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series A Biotechnology companies in 2025–2027 (156 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 15 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 66% of Biotechnology peers (4291 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.